Publicaciones (348) Publicaciones de MARCOS GONZÁLEZ DÍAZ

2024

  1. Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)

    eClinicalMedicine, Vol. 73

  2. Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease

    British Journal of Haematology

  3. Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient

    Biomedicines, Vol. 12, Núm. 1

2023

  1. Characterization of Three Somatic Mutations in the 3′UTR of RRAS2 and Their Inverse Correlation with Lymphocytosis in Chronic Lymphocytic Leukemia

    Cells, Vol. 12, Núm. 23

  2. Clonal architecture and evolutionary history of Waldenström's macroglobulinemia at the single-cell level

    Disease models & mechanisms, Vol. 16, Núm. 8

  3. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

    Blood Advances

  4. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

    Blood Advances, Vol. 7, Núm. 1, pp. 167-173

  5. Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy

    Cancers, Vol. 15, Núm. 12

  6. Systematic Evaluation of Antigenic Stimulation in Chronic Lymphocytic Leukemia: Humoral Immunity as Biomarkers for Disease Evolution

    Cancers, Vol. 15, Núm. 3

2022

  1. A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression

    Blood Advances, Vol. 6, Núm. 21, pp. 5763-5773

2021

  1. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival

    British Journal of Haematology, Vol. 192, Núm. 5, pp. 843-852

  2. Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative

    Annals of Hematology, Vol. 100, Núm. 3, pp. 825-830

  3. Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

    PLoS ONE, Vol. 16, Núm. 9 September

  4. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

    Leukemia, Vol. 35, Núm. 8, pp. 2358-2370

  5. Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping

    British Journal of Haematology, Vol. 195, Núm. 4, pp. 542-551

2020

  1. A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients

    Journal of Molecular Diagnostics, Vol. 22, Núm. 1, pp. 60-71

  2. Biological features and prognostic impact of bone marrow infiltration in patients with diffuse large b-cell lymphoma

    Cancers, Vol. 12, Núm. 2

  3. Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country

    Experimental Hematology and Oncology

  4. Genomic analysis of a familial myelodysplasia/acute myeloid leukemia and inherited RUNX1 mutations without a pre-existing platelet disorder

    Leukemia and Lymphoma

  5. Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients

    British Journal of Haematology, Vol. 189, Núm. 4, pp. 718-730